Lupus & antiphospholipid syndrome
Metabolomic analysis suggests thiamine monophosphate as a potential marker for mesenchymal stem cell transplantation outcomes in patients with SLE
Authors' conclusion
This study concludes that TMP is a potential biomarker that can predict the efficacy of MSCT in treating SLE
Study context
- Population
- Patients with SLE treated with mesenchymal stem cell transplantation (MSCT)
- Participants
- 20 patients
- Comparison
- Plasma metabolic profiles before vs after MSCT
- Outcome
- Metabolic markers associated with successful treatment by MSCT
Methodological detailsmetabolomic analysis, before-and-after comparison
- Metabolomic analysis
- Before-and-after comparison
Main finding
As reported in the abstract
Metabolite changes after MSCT
Metabolites detected
18 121
Metabolites with significant changes post-treatment, clearly distinguished pre vs post by principal component analysis (PCA)
1152
ROC: Thiamine monophosphate (TMP) level change most predictive of treatment success; increase indicating good response
35%
Further findings
Clinical outcomes after MSCT · median follow-up 180 days
- Decreased SLE Disease Activity Index scores, urine protein/creatinine ratios and ESR; increased complement C3 and C4, haemoglobin and platelets
Original publication
Metabolomic analysis suggests thiamine monophosphate as a potential marker for mesenchymal stem cell transplantation outcomes in patients with SLE. Lupus Sci Med. Published 12 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →